和中国一样，俄罗斯也是药品行业十分具有发展潜力的新兴市场，同时对药品进口的依赖度也十分高，是中国十分重要的药品出口地。据悉，为了保护国内制药行业的发展，俄罗斯将对进口药品出台限制政策，此举或将影响我国医药工业的出口。

And China,Russia is also very pharmaceutical industry has the potential for the development of emerging markets,At the same time the drug import dependency is also very high,Is China's important drug exports.It is reported,In order to protect domestic pharmaceutical industry development,Russia will come for imported drugs limit policy,The move or will influence our country medicine industrial export.

　　业内人士指出，未来几年，高增长的新兴市场将是推动全球医药市场增长的主力军。到2016年，国际医药产品市场平均年增长率将达到4.5%。其中，新兴市场接近12%，尤其是中国、巴西、印度和俄罗斯的医药市场增长将远超平均值。预计到2016年，新兴市场在全球医药行业的市场份额将达到40%左右。

The personage inside course of study points out that,In the coming years,The growth in emerging markets will be driving the global pharmaceutical market the main force of growth.By 2016,International pharmaceutical products market average annual growth rate will reach 4.5%.the,Emerging markets close to 12%,Especially in China/Brazil/India and Russia's medical market growth will far above average.It is estimated that by 2016,Emerging markets in the global pharmaceutical industry market share will reach 40%.

　　中俄两国是备受关注的新兴医药市场，由于其各自医药产业发展具有差异性和互补性，因此两国在医药领域有着广阔的合作空间。经过多年的磨合，两国市场成熟度、开放度越来越高，企业合作越来越密切。俄罗斯70～80%的药品需要进口。

China and Russia are of concern emerging medical market,Because of their own medicine industry development has the difference and complementarity,So the two countries in the field of medicine has a broad cooperation space.After years of running in,The two countries market maturity/Openness is more and more high,Enterprise cooperation more and more closely.Russia 70 ~ 80% of drugs need to import.

　　据了解，上世纪90年代，俄罗斯向全球打开了药品市场大门。目前，俄罗斯已有630家国外医药企业和约350家本土药企。尽管市场规模以年均20%以上的速度增长，但其本土生产药品的市场占有率却以每年1～2%的速度在下降，进口药品几乎垄断了俄罗斯国家药品的采购环节。

It is understood,In the 1990 s,Russia to the global pharmaceutical market opened the door.At present,Russia has 630 foreign pharmaceutical enterprise and 350 local medicine enterprises.Despite the size of the market at an annual rate of more than 20% growth,But the local production of pharmaceuticals market share but with every year 1 ~ 2% of the speed on the decline,Imported drugs is almost a monopoly of the Russian national drug purchase link.

　　日前，从俄罗斯方面传来消息，俄罗斯工业和贸易部公布了联邦政府令草案，旨在限制在国家订购时采购进口药品。俄罗斯工业和贸易部要在一个月内核准一项标准，按此标准，在俄罗斯境内生产的药品并被用作外国产药品的组成部分，可以归入原产自俄罗斯的药品之列。

a,Transmits a message from Russia,The Russian ministry of trade and industry announced a temporary federal draft,In order to limit state when purchasing imported drugs.The Russian ministry of trade and industry in a month to approve a standard,According to this standard,In the Russian domestic production of drugs and used as the domestic part of the drug,Can be classified as origin from Russia in the drug list.

　　有关专家指出，作为中国十分重要的药品出口市场之一，俄罗斯此举势必对我国的药品出口贸易造成一定的影响，国内企业必须及时调整政策，以应对这一变化。

Concerned expert points out,As the very important one of drug export market,Russia will move to China's drug export trade produce certain effect,Domestic enterprises must adjust policy,In response to the change.